Patents by Inventor Nicholas R. Wurtz

Nicholas R. Wurtz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OXOPYRROLIDINE FPR2 AGONISTS
    Publication number: 20230348426
    Abstract: The disclosure relates to compounds of Formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Application
    Filed: July 8, 2021
    Publication date: November 2, 2023
    Inventors: Pravin Sudhakar Shirude, Chandrasekhar Reddy Rachamreddy, Amit Kumar Chattopadhyay, Balaji Seshadri, Vishweshwaraiah Baligar, Sudhakara Reddy Madduri, Ellen K. Kick, Nicholas R. Wurtz
  • OXOPYRROLIDINE UREA FPR2 AGONISTS
    Publication number: 20230303513
    Abstract: The disclosure relates to compounds of Formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Application
    Filed: August 11, 2021
    Publication date: September 28, 2023
    Inventors: Pravin Sudhakar Shirude, Chandrasekhar Reddy Rachamreddy, Vishweshwaraiah Baligar, Balaji Seshadri, Sudhakara Reddy Madduri, Ellen K. Kick, Nicholas R. Wurtz
  • PYRAZOLONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS
    Publication number: 20230250063
    Abstract: The disclosure relates to compounds of formula I, which are formyl peptide 2 (FPR2) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Application
    Filed: July 8, 2021
    Publication date: August 10, 2023
    Inventors: James A. Johnson, Zulan Pi, Nicholas R. Wurtz, Joanne M. Smallheer, Meriah Neissel Valente, Ellen K. Kick, Charles G. Clark, Pravin Sudhaka Shirude, Balaji Kumar Seshadri, Amit Kumar Chattopadhyay
  • Phenylpyrrolidinone formyl peptide 2 receptor agonists
    Patent number: 11708327
    Abstract: The disclosure relates to compounds of Formulae (I)-(IX), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: July 25, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Pravin Sudhakar Shirude, Vishweshwaraiah Baligar, Balaji Seshadri, Amit Kumar Chattopadhyay, Nicholas R. Wurtz, Ellen K. Kick
  • Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
    Patent number: 11530183
    Abstract: The disclosure relates to compounds of formula I, which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Grant
    Filed: June 11, 2020
    Date of Patent: December 20, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Nicholas R. Wurtz, Pravin Sudhakar Shirude
  • BIARYL DIALKYL PHOSPHINE OXIDE FPR2 AGONISTS
    Publication number: 20220298186
    Abstract: The disclosure relates to compounds of Formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Application
    Filed: June 16, 2020
    Publication date: September 22, 2022
    Inventors: Pravin Sudhakar Shirude, Amit Kumar Chattopadhyay, Ellen K. Kick, Nicholas R. Wurtz
  • PYRROLIDINONE DERIVATIVES AS FORMYL PEPTIDE 2 RECEPTOR AGONISTS
    Publication number: 20220002281
    Abstract: The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, and related diseases.
    Type: Application
    Filed: November 25, 2019
    Publication date: January 6, 2022
    Inventors: Nicholas R. WURTZ, James A. JOHNSON, Zulan PI, Andrew Quoc VIET
  • PHENYLPYRROLIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS
    Publication number: 20210371378
    Abstract: The disclosure relates to compounds of Formulae (I)-(IX), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Application
    Filed: August 12, 2021
    Publication date: December 2, 2021
    Inventors: Pravin Sudhakar Shirude, Vishweshwaraiah Baligar, Balaji Seshadri, Amit Kumar Chattopadhyay, Nicholas R. Wurtz, Ellen K. Kick
  • Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
    Patent number: 11186544
    Abstract: The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: November 30, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Nicholas R. Wurtz, Pravin Sudhakar Shirude, Andrew Quoc Viet
  • Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists
    Patent number: 11180490
    Abstract: The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, and related diseases.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: November 23, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Joanne M. Smallheer, Nicholas R. Wurtz, Meriah Neissel Valente, Karen A. Rossi, Ellen K. Kick
  • Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
    Patent number: 11124494
    Abstract: The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, and related diseases.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: September 21, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Pravin Sudhakar Shirude, Amit Kumar Chattopadhyay, Nicholas R. Wurtz
  • Phenylpyrrolidinone formyl peptide 2 receptor agonists
    Patent number: 11117861
    Abstract: The disclosure relates to compounds of Formulae (I)-(IX), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: September 14, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Pravin Sudhakar Shirude, Vishweshwaraiah Baligar, Balaji Seshadri, Amit Kumar Chattopadhyay, Nicholas R. Wurtz, Ellen K. Kick
  • Piperidinone formyl peptide 2 receptor agonists
    Patent number: 11008301
    Abstract: The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, and related diseases.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: May 18, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Pravin Sudhakar Shirude, Amit Kumar Chattopadhyay, Chandrasekhar Rachamreddy, Nicholas R. Wurtz, Ellen K. Kick
  • Triazolopyridine inhibitors of myeloperoxidase and/or EPX
    Patent number: 11008317
    Abstract: The present invention provides compounds of Formula (I); wherein the substituents are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, and may be useful for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: May 18, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ellen K. Kick, Joanne M. Smallheer, Scott A. Shaw, Benjamin P. Vokits, Andrew K. Dilger, Charles G. Clark, Meriah Neissel Valente, Sutjano Jusuf, Nicholas R. Wurtz
  • Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase
    Patent number: 10981879
    Abstract: The present invention provides compounds of Formula (I): wherein A, X and Y are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: April 20, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Andrew Quoc Viet, Nicholas R. Wurtz
  • ARYL HETEROCYCLIC PIPERIDINONE FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS
    Publication number: 20210078971
    Abstract: The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, and related diseases.
    Type: Application
    Filed: June 8, 2018
    Publication date: March 18, 2021
    Inventors: Pravin Sudhakar Shirude, Amit Kuma Chattopadhyay, Nicholas R. Wurtz
  • PIPERIDINONE FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS
    Publication number: 20200299237
    Abstract: The disclosure relates to compounds of formula I, which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Application
    Filed: June 11, 2020
    Publication date: September 24, 2020
    Inventors: Nicholas R. Wurtz, Pravin Sudhakar Shirude
  • TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX
    Publication number: 20200291016
    Abstract: The present invention provides compounds of Formula (I); wherein the substituents are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, and may be useful for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Application
    Filed: March 16, 2017
    Publication date: September 17, 2020
    Inventors: Ellen K. Kick, Joanne M. Smalheer, Scott A. Shaw, Benjiman P. Vokits, Andrew K. Dilger, Charles G. Clark, Meriah Neissel Valente, Sutjano Jusuf, Nicholas R. Wurtz
  • PHENYLPYRROLIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS
    Publication number: 20200255375
    Abstract: The disclosure relates to compounds of Formulae (I)-(IX), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Application
    Filed: April 24, 2020
    Publication date: August 13, 2020
    Inventors: Pravin Sudhakar Shirude, Vishweshwaraiah Baligar, Balaji Seshadri, Amit Kumar Chattopadhyay, Nicholas R. Wurtz, Ellen K. Kick
  • Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
    Patent number: 10717708
    Abstract: The disclosure relates to compounds of formula I, which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: July 21, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Nicholas R. Wurtz, Pravin Sudhakar Shirude